Subscribe to Search results

The Ministry of Health agreed with the SHHD that the PFC would fractionate plasma for the NHS using plasma collected by the Newcastle, Leeds, Manchester and Liverpool regions.

Published on:

The Blood Transfusion Public Expenditure Survey Committee issued a report regarding a statement on forecast assessments.

Published on:

The Scottish Home and Health Department suggested that there should be a management policy committee covering both the Blood Products Laboratory and the Protein Fractionation Centre to ensure that a common production policy would apply to both laboratories.

Published on:

It was not until 1965 that planning for a 1972 extension to the Blood Products Laboratory, which then followed, contemplated accommodating the fractionation of plasma on any scale. This was a necessary step in producing clotting factor concentrates, though the main reason for the expansion at the time was to produce more immunoglobulin to prevent rubella in pregnancy, following an outbreak.

Published on:

Pressure on the Government to act on increasing the supply of plasma was exerted by clinicians, by the medical press, by NBTS, and by the advisory bodies which had been set up.

Published on:

The setting up of a Joint Steering Committee on Blood Products Production was precipitated by the grant of product licences to two commercial firms "which might entail large sums being spent by NHS authorities on these products."

Published on:

The Scottish CMO, Sir John Brotherson, wrote from Scotland offering further support for blood product production capabilities south of the border.

Published on:

It had been decided that 1,000 litres of fresh or fresh frozen plasma could be processed weekly by PFC, using pools of eight litres. This size of pool could be handled conveniently and quickly and was supported by clinicians using the material.

Published on:

It was considered that, as there was only a small possibility of expansion at Elstree, Edinburgh should be prepared to cope with the requirements of a larger part of England than originally intended so that the total growth of requirement could be handled by the two Blood Products Units. Dr Maycock considered that this approach to long-term planning was the only correct procedure.

Published on:

The DHSS invested £400,000 in the Protein Fractionation Centre towards the capital costs.

Published on:

Dr Maycock indicated that he expected one third of the plasma from England would be processed at Liberton.

Published on:

At the end of December 1969 it was known to be unlikely that the Protein Fractionation Centre would begin production before the second half of 1973.

Published on:

Treasury approval was given to a final cost limit of £1,728,079 for the work on the Protein Fractionation Centre.

Published on:

The Expert Group on the Treatment of Haemophilia emphasised the importance of taking a UK view of provision for haemophilia therapy.

Published on:

At the minimum level of working, it was expected that 1,000 litres of plasma would come from Scotland each week, and the remaining 500 litres would come from England. John Watt questioned how this would work since there was no available plasma in England available at that time.

Published on:

In his evidence, Dr Foster explained that John Watt considered a fractionation centre should support a population of at least 15 million to be economically viable meaning that the population of Scotland was too small, in his opinion, for the Protein Fractionation Centre to be economically viable, and he saw England as essential to the future survival of the Centre, as well as of benefit to England.

Published on:

The Scottish Home Health Department asked the DHSS when the Protein Fractionation Centre would be provided with English plasma for fractionation.

Published on:

It was reported at a DHSS meeting that the Minister of State stressed the need for cooperation between Scotland and England in manufacturing blood products.

Published on:

It was agreed at a SNBTS meeting that no start should be made on the large-scale processing of plasma from England and Wales until a plan had been agreed by transfusion directors.

Published on:

Transfusion directors agreed at an SNBTS meeting that Mr Watt could process a limited amount of plasma from BPL to establish yield and costs.

Published on: